16. Oktober 2020 German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test 4. Juni 2020 Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer 3. Dezember 2019 Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium 25. Juni 2019 Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer 9. Mai 2019 New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy 30. April 2019 EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer 19. Dezember 2018 EndoPredict® Test Receives Positive NICE Recommendation for Patients with Early Breast Cancer 7. Dezember 2018 Prospective Study Demonstrates EndoPredict® Can Guide Chemotherapy Decision For Women with Early-Stage Breast Cancer 7. Dezember 2018 Myriad Announces Important New Data for Its EndoPredict® Breast Cancer Test Will Be Presented at the 2018 San Antonio Breast Cancer Symposium 15. Februar 2018 JAMA Oncology Publication Demonstrates EndoPredict® (EPClin) Significantly Outperforms Oncotype DX® Recurrence Score in Early-Stage Breast Cancer 8. Dezember 2017 Myriad Genetics Presents Results From Two Important EndoPredict® Studies at the 2017 San Antonio Breast Cancer Symposium 26. Oktober 2017 EndoPredict (EPclin) Shown in Second Study to be More Effective than Oncotype DX® (RS) in Women with Intermediate Risk of Breast Cancer Recurrence 13. März 2017 Myriad Genetics Launches the EndoPredict® Test in the United States for Patients with Breast Cancer 9. Dezember 2016 The EndoPredict® Test Significantly Outperforms the First-Generation Test in Predicting the Risk of Node-Negative and Node-Positive Breast Cancer Recurrence
